Poland· PL-100465456
Vyepti
A eptinezumab product containing eptinezumabum, registered in Poland by H. Lundbeck A/S. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Eptinezumab is registered in 14 of 19 countries.
Countries holding a registration under ATC N02CD05 (eptinezumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Eptinezumab · ATC N02CD05
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Eptinezumabum
- Manufacturer
- H. Lundbeck A/S
- Country
- Poland (PL)
- ATC code
- N02CD05
- ATC class
- Eptinezumab
- Defined daily dose
- 1.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05702150155733
- gtin05702150155085
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Eptinezumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandVyepti 300 mg/3 ml, Konzentrat zur Herstellung einer InfusionslösungLundbeck (Schweiz) AG
- FinlandVYEPTIAbacus Medicine A/S
- CzechiaVYEPTIH. Lundbeck A/S, Valby
- United StatesVyeptiLundbeck Pharmaceuticals LLC
- SpainVYEPTI 100 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONH. Lundbeck A/S
- BelgiumVyepti 100 mgH. Lundbeck
- CanadaVYEPTILUNDBECK CANADA INC
- NetherlandsVyepti 100 mg/ml, concentraat voor oplossing voor infusieH. Lundbeck A/S
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Vyepti
- Norway · Vyepti
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dac922aa-050f-4b86-bc7f-ab0d276c604e GET /v1/drugs/dac922aa-050f-4b86-bc7f-ab0d276c604e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "100 mg/ml",
"packaging": "05702150155733 ¦ Rpz ¦ EU/1/21/1599/001 ¦ 144149\n1 fiol. 1 ml\nRpz ¦ EU/1/21/1599/002 ¦ 152363\n3 fiol. 4 ml\n05702150155085 ¦ Rpz ¦ EU/1/21/1599/001 ¦ 168202\n1 fiol. 1 ml",
"substance": "Eptinezumabum 100 mg/ml",
"common_name": "Eptinezumabum",
"pl_product_id": "100465456",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about eptinezumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.